Ascendis Pharma’s (ASND) Palopegteriparatide is a once-daily PTH replacement therapy approved by the FDA and EMA and branded as Yorvipath. It's the only approved drug for HP, although it's not yet ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

Rates of survival after out-of-hospital cardiac arrest (OHCA) have not fully bounced back since the COVID-19 pandemic, ...

If health is wealth then far too many Britons are bankrupt. In the UK, 65.1 per cent of avoidable deaths in 2022 were ...